AB SCIEX Announces Biologics Initiative

Mass spectrometry leader’s BiologicsFocus programs address industry shift to biopharmaceuticals

AB SCIEX Announces Biologics Initiative

AB SCIEXAnthony Petrucci, 1-508-383-7961 (Media)

, a global leader in life science analytical technologies, today announced a global initiative focused on biologics. This new initiative is in response to the fundamental shift of the pharmaceutical industry into biopharmaceutical development. AB SCIEX’s consists of four components: new product development; beta software evaluation program; one-on-one connections program; and forums for sharing the latest advancements in biologics across the scientific community. The company revealed this initiative today at the International Mass Spectrometry Conference (IMSC) in Japan.

The Initiative represents AB SCIEX’s open approach to producing comprehensive biologics solutions by involving scientists in industry and academia in the development of new tools. AB SCIEX already has a proven track record with its for bio-therapeutics characterization. The company is now taking the next important step to address an industry-wide need – the development of data analysis solutions to simplify and accelerate biologics development.

Forty-two percent of new drugs in drug development pipelines of pharmaceutical companies are based on biologics, according to survey results published earlier this year by EvaluatePharma, a market research firm. Moreover, the development of biosimilars, or “generic” biologic drugs, is dramatically increasing globally in response to legislation enabling their licensure in the United States.

The trend is to transition away from the traditional model of drug development, which is based on small molecule analysis. The promise of biopharmaceuticals is that pharmaceutical companies will be able to more rapidly develop more effective drugs with fewer side effects. Recent advancements in technologies for large molecule analysis, such as protein characterization, have sped up the shift to bio-therapeutics.

AB SCIEX’s biologics initiative includes the following programs:

“We recognize biologics for its strategic importance to the pharmaceutical industry,” said . “AB SCIEX is well-positioned with our industry-leading hardware platforms and our unique combination of strengths in both large molecule characterization and pharmaceutical analysis. We are working closely with pharmaceutical scientists to develop and shape new software solutions that directly address the needs and requirements for the new frontier of drug discovery and development. We continue to be a trusted partner with pharmaceutical companies and academics worldwide.”

AB SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face. The company’s global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 25 years of proven innovation, AB SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information about the company, go to . Follow AB SCIEX on , Twitter , and .

The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX is being used under license.

© 2012. AB SCIEX.

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.